Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P43 vs Stelara in Moderate to Severe Plaque Psoriasis
2020-001045-39Phase 3Completed
- Sponsor
- Celltrion
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ustekinumab CT-P43 in plaque psoriasis (2 arms), sponsored by Celltrion. Started Oct 2020; status: completed.
02
Drugs
ustekinumab CT-P43
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2020-001045-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001045-39.